chufangao/CTO huggingface dataset:
Clinical trial NCT03950037: SANCC: Clinical Trial Early Intervention
Official title: An Open-label Non-randomized Phase IIa Trial to Evaluate Safety of Early Intervention in Asymptomatic Subarachnoid Neurocysticercosis
Sponsor: Oregon Health and Science University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to complete due to SARS-CoV-2 pandemic
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-01-01
Primary completion date: 2023-04-30
Completion date: 2023-04-30
Plan to share individual participant data: YES
IPD sharing description: Anonymized patient data for primary and secondary outcomes will be made available.
IPD time frame: 6 months after trial completion
IPD access criteria: Data access requests will be reviewed by the principal investigators. Requestors will be required to sign a Data Use Agreement.
Clinical trial NCT02495103: Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Official title: Phase I/II Trial of Vandetanib in Combination With Metformin in Subjects With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma
Sponsor: National Institutes of Health Clinical Center (CC) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Vandetanib is no longer available as Sanofi has decided not to provide additional drug. All subjects are off-study.
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-08-26
Primary completion date: 2020-02-06
Completion date: 2020-02-06
Plan to share individual participant data: NO
Clinical trial NCT04428775: A Safety and Biomarker Study of ALZT-OP1a in Subjects With Mild-Moderate ALS Disease
Official title: A Phase IIa, Randomized, Open-label, Multi-Center, Multi-Dose Study to Evaluate the Effects of ALZT-OP1a in Subjects With Mild-Moderate Stage Amyotrophic Lateral Sclerosis (ALS)
Sponsor: AZTherapies, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Low enrollment
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-09-08
Primary completion date: 2021-10-01
Completion date: 2021-10-01
Plan to share individual participant data: NO
Clinical trial NCT04322214: Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat
Official title: Clinical Trial to Evaluate Pharmacological Interactions Between γ-hydroxybutyrate (GHB) and Cobicistat
Acronym: GHB_Cobi
Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-30
Primary completion date: 2020-03-30
Completion date: 2020-04-30
Clinical trial NCT03884465: Hemodynamic Evaluation of Dose-response and Safety of Dry Powder Inhalation of Treprostinil
Official title: A Two Part, Phase 2 Open-label, Multi-Centre, Dose Escalation Hemodynamic Study to Evaluate Dose-Response and Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Subjects
Sponsor: Liquidia Technologies, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: COVID
Enrollment: 15.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-11
Primary completion date: 2020-12-23
Completion date: 2020-12-23
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03481660: A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
Official title: A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema
Acronym: KITE
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 360.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-07-27
Primary completion date: 2020-06-29
Completion date: 2021-06-08
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03024437: Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Official title: A Phase I/II Study to Evaluate the Safety, Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Sponsor: Indiana University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: SUSPENDED 
Why stopped: Major review underway
Enrollment: 72.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2017-06-29
Primary completion date: 2023-06-30
Completion date: 2024-06-30
Clinical trial NCT04726332: Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Official title: A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XL102 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
Sponsor: Exelixis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Business reasons
Enrollment: 52.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-02-10
Primary completion date: 2024-05-02
Completion date: 2024-05-02
Clinical trial NCT03388814: Speeding Recovery From Pain and Opioid Use
Official title: Speeding Recovery From Pain and Opioid Use After Mastectomy and Breast Reconstruction Surgery
Sponsor: Wake Forest University Health Sciences (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: Lack of Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-30
Primary completion date: 2020-06-30
Completion date: 2020-06-30
Clinical trial NCT04167345: Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects
Sponsor: Vertex Pharmaceuticals Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: at Sponsor's discretion
Enrollment: 48.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-01-13
Primary completion date: 2020-11-14
Completion date: 2020-11-14
Limitations and caveats: During the study, elevated liver enzymes (AST/ALT) were observed in several participants and analysis of available pharmacokinetics data indicated that VX-814 exposures achieved were low. Based on these data, Vertex concluded that it would not be feasible to safely reach targeted exposure levels with VX-814. Thus, the study was terminated early at the sponsor's discretion. Given the study was terminated early, the data are incomplete, and results should be interpreted with caution.
Plan to share individual participant data: NO
IPD sharing description: Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Clinical trial NCT04806035: Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Official title: A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Sponsor: TG Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic/Business Decision
Enrollment: 21.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-04-28
Primary completion date: 2024-06-12
Completion date: 2024-06-12
Clinical trial NCT05219864: Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1
Official title: Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1 (TRuE-CHE1): A Phase 3, Double-Blind, Randomized, 16-Week, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Open-Label Extension Period in Adults With Chronic Hand Eczema
Acronym: TRuE-CHE1
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Business decision; no safety concerns.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-01-31
Primary completion date: 2024-04-25
Completion date: 2024-09-22
Plan to share individual participant data: NO
Clinical trial NCT04344288: Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection
Official title: Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection
Acronym: CORTI-Covid
Sponsor: Hospices Civils de Lyon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Competent Authority's decision
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-21
Primary completion date: 2020-08-18
Completion date: 2020-08-18
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04776044: Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
Official title: RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
Acronym: RESPIRE
Sponsor: Atriva Therapeutics GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: general circumstances around COVID-19 and current availability of hospitalized patients
Enrollment: 133.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-12
Primary completion date: 2022-06-06
Completion date: 2022-08-09
Clinical trial NCT04068610: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
Official title: A Phase Ib/II, Open-label, Multicenter Study of Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First-line Therapy in Metastatic Microsatellite-stable Colorectal Cancer (COLUMBIA-1)
Sponsor: MedImmune LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: On 17 February 2022, the decision was made to terminate the clinical study because superior efficacy was not observed for the novel study drug combinations under investigation.
Enrollment: 61.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-13
Primary completion date: 2022-10-10
Completion date: 2022-10-10
Baseline population: As-treated population included all participants who received any study drugs and were analyzed according to the treatment they actually received.
Limitations and caveats: On 17 February 2022, the decision was made to terminate the clinical study because superior efficacy was not observed for the novel study drug combinations under investigation.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04228783: A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN®-Filo in Adult Participants
Sponsor: Janssen Vaccines & Prevention B.V. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 974.0 (ACTUAL)
Number of arms: 6.0
Start date: 2020-02-18
Primary completion date: 2022-04-25
Completion date: 2022-04-25
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency.~As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT04671836: Lorazepam Effects on Neuroimaging Measures
Official title: Lorazepam Effects on Neuroimaging Measures: A Pilot Study
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: No longer interested in conducing study
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2022-12-31
Completion date: 2022-12-31
Plan to share individual participant data: NO
Clinical trial NCT02787005: Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
Official title: Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 388.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-07-01
Primary completion date: 2022-02-28
Completion date: 2022-02-28
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05079789: Amiloride in Nephrotic Syndrome
Official title: Randomized, Controlled Interventional Trial to Investigate the Efficacy of Amiloride for the Treatment of Edema in Human Nephrotic Syndrome
Acronym: AMILOR
Sponsor: University Hospital Tuebingen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Low recruiting rate and decision to evaluate as pilot study
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-08
Primary completion date: 2022-11-05
Completion date: 2022-11-20
Clinical trial NCT04030000: Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation
Official title: A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma
Sponsor: Northwell Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: could not enroll anyone due to staff changes
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-05-20
Primary completion date: 2022-08-30
Completion date: 2023-01-30
Plan to share individual participant data: NO
Clinical trial NCT02663895: Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Official title: A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-31
Primary completion date: 2020-05-13
Completion date: 2020-05-13
Plan to share individual participant data: NO
Clinical trial NCT02914522: Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
Official title: Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
Acronym: SELECTION
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1351.0 (ACTUAL)
Number of arms: 11.0
Start date: 2016-11-14
Primary completion date: 2020-03-31
Completion date: 2020-03-31
Baseline population: Safety Analysis Set for the Induction Study (Cohorts A and B) included all participants who took at least 1 dose of study drug in the Induction Study.
Plan to share individual participant data: NO
Clinical trial NCT02667327: A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer
Official title: A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)
Sponsor: Xequel Bio, Inc. (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor Decision (No safety or efficacy concerns)
Enrollment: 124.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-11-21
Primary completion date: 2020-05-27
Completion date: 2020-05-27
Plan to share individual participant data: NO
Clinical trial NCT01711242: Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma
Official title: Phase II Randomized Trial of Adjuvant XELOX Chemotherapy and XELOX With Concurrent Capecitabine and Radiotherapy for Gastric Adenocarcinoma With D2 Dissection
Sponsor: Wenzhou Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 208.0 (ACTUAL)
Number of arms: 2.0
Start date: 2012-01-31
Primary completion date: 2020-01-31
Completion date: 2021-01-31
Clinical trial NCT04478825: Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
Official title: An Open Label, Proof of Mechanism Study to Explore the Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
Sponsor: Bridge Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Internal Company Decision
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-01
Primary completion date: 2021-08-04
Completion date: 2021-08-24
Clinical trial NCT03693170: Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
Official title: Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Acronym: ANCHOR-CRC
Sponsor: Pierre Fabre Medicament (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 95.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-01-17
Primary completion date: 2020-06-29
Completion date: 2023-04-27
Limitations and caveats: The absence of a comparator arm should be noted as a limitation. In addition, the short duration of the follow-up at the data cut-off date does not allow a robust estimate of OS results.
Clinical trial NCT02393690: Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
Official title: Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Sponsor: Academic and Community Cancer Research United (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-05-04
Primary completion date: 2020-07-17
Completion date: 2023-12-31
Baseline population: All patients registered to protocol treatment are included in this analysis.
Clinical trial NCT04325503: Neurobiological Drivers of Mobility Resilience: The Dopaminergic System
Official title: Neurobiological Drivers of Mobility Resilience: The Dopaminergic System
Acronym: RES
Sponsor: University of Michigan (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-08
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Plan to share individual participant data: NO
IPD sharing description: Results will be provided in publications
Clinical trial NCT03024216: Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Official title: Phase Ib Study Assessing Different Sequencing Regimens of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Sponsor: University of Hawaii (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 37.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-02-06
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04348890: Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis
Official title: A Phase I/II Open-Label, Proof-of-Concept Study of Vamorolone in Children and Adolescents With Mild-Moderately Active Ulcerative Colitis
Sponsor: ReveraGen BioPharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Programmatic decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-01
Primary completion date: 2022-09-01
Completion date: 2022-09-01
Plan to share individual participant data: NO
Clinical trial NCT02961218: Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
Official title: A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-04-05
Primary completion date: 2019-06-27
Completion date: 2020-04-27
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT05293509: Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Official title: Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: 0 accrual
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-02
Primary completion date: 2023-09-18
Completion date: 2023-09-18